Literature DB >> 19877794

Cerebral venous sinus thrombosis: review of the demographics, pathophysiology, current diagnosis, and treatment.

Aristotelis Filippidis1, Eftychia Kapsalaki, Gianna Patramani, Kostas N Fountas.   

Abstract

Cerebral venous sinus thrombosis (CVST) is a rare clinicopathological entity. The incidence of CVST in children and neonates has been reported to be as high as 7 cases per million people, whereas in adults the incidence is 3-4 cases per million. The predisposing factors to this condition are mainly genetic and acquired prothrombotic states and infection. The clinical picture of CVST is nonspecific, highly variable, and can mimic several other clinical conditions. Diagnosis of CVST is established with the implementation of neuroimaging studies, especially MR imaging and venography. Identification and elimination of the underlying cause, anticoagulation, proper management of intracranial hypertension, and anticonvulsant prophylaxis constitute cornerstones of CVST treatment. Newer treatment strategies such as endovascular thrombolysis and decompressive craniectomy have been recently used in the treatment of patients with CVST with variable success rates. Further clinical research must be performed to delineate the exact role of these newer treatments in the management of severe cases of CVST. The recent advances in the diagnosis and treatment of patients with CVST have significantly lowered the associated mortality and morbidity and have improved the outcome of these patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19877794     DOI: 10.3171/2009.8.FOCUS09167

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  33 in total

1.  A case of cerebral venous thrombosis in a 77-year-old white man.

Authors:  Dakshinamurty Gullapalli; Taral R Sharma; Dennis G Duncan; Urvi R Shah
Journal:  Prim Care Companion CNS Disord       Date:  2011

2.  Cerebral venous sinus thrombosis with parieto-temporal infarct in a young woman.

Authors:  Rayna Patel; Koshy Thomas; Sami Khan
Journal:  BMJ Case Rep       Date:  2013-06-18

3.  A novel protein S gene mutation combined with protein S Tokushima mutation in a patient with superior sagittal sinus thrombosis.

Authors:  Akihiro Shindo; Makoto Ikejiri; Yuichiro Ii; Kaname Nakatani; Hideo Wada; Tsutomu Nobori; Hidekazu Tomimoto
Journal:  J Neurol       Date:  2011-06-07       Impact factor: 4.849

4.  Resolution of brainstem edema after treatment of a dural tentorial arteriovenous fistula.

Authors:  Hortensia Alvarez; Deanna Sasaki-Adams; Mauricio Castillo
Journal:  Interv Neuroradiol       Date:  2015-06-26       Impact factor: 1.610

5.  Neuro-ophthalmological Features of Cerebral Venous Sinus Thrombosis.

Authors:  N Eliseeva; N Serova; S Yakovlev; K Mikeladze; Y Arkhangelskaya; S Gasparyan
Journal:  Neuroophthalmology       Date:  2014-11-24

Review 6.  Cerebral Venous Sinus Thrombosis: Successful Treatment of Two Patients Using the Penumbra System and Review of Endovascular Approaches.

Authors:  Weihua Liao; Yunhai Liu; Wenping Gu; Jie Yang; Changqing Chen; Fan Liu; Feiyue Zeng; Xiaoyi Wang
Journal:  Neuroradiol J       Date:  2015-04-13

Review 7.  Cerebral venous sinus thrombosis associated with bulimia nervosa.

Authors:  Christopher McAloon; Saad A M Saeed
Journal:  BMJ Case Rep       Date:  2011-02-23

8.  Dural venous sinus thrombosis in anaplastic astrocytoma following concurrent temozolomide and focal brain radiotherapy plus bevacizumab.

Authors:  J A Vargo; B M Snelling; E R Ghareeb; K John; J N Frame; J H Schmidt; K B Peters
Journal:  J Neurooncol       Date:  2011-01-08       Impact factor: 4.130

Review 9.  Cerebral venous and dural sinus thrombosis* : state-of-the-art imaging.

Authors:  Jennifer Linn; Hartmut Brückmann
Journal:  Clin Neuroradiol       Date:  2010-02-28       Impact factor: 3.649

Review 10.  [Therapeutic options in malignant cerebral venous and sinus thrombosis].

Authors:  S Schönenberger; C Geisbüsch; S Nagel; W Hacke; J Bösel
Journal:  Nervenarzt       Date:  2014-02       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.